GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target

Deep News07-09

GTHT Securities has released a research report initiating coverage on KEYMED BIO-B (02162). The firm has assigned a Buy rating to the company's shares.

The valuation was conducted using a Discounted Cash Flow (DCF) absolute valuation method, resulting in a target price of RMB 120.85. Converting this at an exchange rate of 1 Hong Kong dollar to RMB 0.87 gives an equivalent target price of HK$138.91.

The report forecasts the company's revenue for the years 2026 to 2028 to be RMB 3.090 billion, RMB 2.156 billion, and RMB 3.085 billion, respectively. The significant revenue increase projected for 2026 is primarily attributed to an upfront payment of US$257 million that KEYMED BIO is expected to receive as a shareholder of Ouro.

For the same period, GTHT Securities predicts the company's net profit attributable to shareholders will be RMB 1.105 billion in 2026, followed by a loss of RMB 63 million in 2027, and a return to profit of RMB 364 million in 2028.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114859510?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114859510","market":"hk","top_or_hot":-1,"title":"GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target","media":"Deep News","content":"<p>GTHT Securities has released a research report initiating coverage on <b>KEYMED BIO-B</b> (<b>02162</b>). The firm has assigned a Buy rating to the company's shares.<br><br>The valuation was conducted using a Discounted Cash Flow (DCF) absolute valuation method, resulting in a target price of RMB 120.85. Converting this at an exchange rate of 1 Hong Kong dollar to RMB 0.87 gives an equivalent target price of HK$138.91.<br><br>The report forecasts the company's revenue for the years 2026 to 2028 to be RMB 3.090 billion, RMB 2.156 billion, and RMB 3.085 billion, respectively. The significant revenue increase projected for 2026 is primarily attributed to an upfront payment of US$257 million that KEYMED BIO is expected to receive as a shareholder of Ouro.<br><br>For the same period, GTHT Securities predicts the company's net profit attributable to shareholders will be RMB 1.105 billion in 2026, followed by a loss of RMB 63 million in 2027, and a return to profit of RMB 364 million in 2028.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-09 14:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GTHT Securities has released a research report initiating coverage on <b>KEYMED BIO-B</b> (<b>02162</b>). The firm has assigned a Buy rating to the company's shares.<br><br>The valuation was conducted using a Discounted Cash Flow (DCF) absolute valuation method, resulting in a target price of RMB 120.85. Converting this at an exchange rate of 1 Hong Kong dollar to RMB 0.87 gives an equivalent target price of HK$138.91.<br><br>The report forecasts the company's revenue for the years 2026 to 2028 to be RMB 3.090 billion, RMB 2.156 billion, and RMB 3.085 billion, respectively. The significant revenue increase projected for 2026 is primarily attributed to an upfront payment of US$257 million that KEYMED BIO is expected to receive as a shareholder of Ouro.<br><br>For the same period, GTHT Securities predicts the company's net profit attributable to shareholders will be RMB 1.105 billion in 2026, followed by a loss of RMB 63 million in 2027, and a return to profit of RMB 364 million in 2028.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"","article_id":"1114859510","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114859510","pubTimestamp":1783578688,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"GTHT Securities has released a research report initiating coverage on KEYMED BIO-B (02162). The firm has assigned a Buy rating to the company's shares.The valuation was conducted using a Discounted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","BK1587":"次新股","BK1574":"生物医药B类股","BK1147":"投资银行业与经纪业","BK1161":"生物科技","BK1564":"中资券商股","02162":"康诺亚-B","02611":"国泰海通","BK1583":"高瓴概念","EWH":"香港ETF-iShares MSCI"},"translate_title":"GTHT证券首次给予KEYMED BIO-B买入评级，目标价138.91港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"02162":1,"EWH":1,"02611":1},"content_text":"GTHT Securities has released a research report initiating coverage on KEYMED BIO-B (02162). The firm has assigned a Buy rating to the company's shares.The valuation was conducted using a Discounted Cash Flow (DCF) absolute valuation method, resulting in a target price of RMB 120.85. Converting this at an exchange rate of 1 Hong Kong dollar to RMB 0.87 gives an equivalent target price of HK$138.91.The report forecasts the company's revenue for the years 2026 to 2028 to be RMB 3.090 billion, RMB 2.156 billion, and RMB 3.085 billion, respectively. The significant revenue increase projected for 2026 is primarily attributed to an upfront payment of US$257 million that KEYMED BIO is expected to receive as a shareholder of Ouro.For the same period, GTHT Securities predicts the company's net profit attributable to shareholders will be RMB 1.105 billion in 2026, followed by a loss of RMB 63 million in 2027, and a return to profit of RMB 364 million in 2028.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114859510","isCrawlerRequest":true}